These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32442885)

  • 1. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.
    Paz-Zulueta M; Parás-Bravo P; Cantarero-Prieto D; Blázquez-Fernández C; Oterino-Durán A
    Mult Scler Relat Disord; 2020 Aug; 43():102162. PubMed ID: 32442885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.
    Dahham J; Rizk R; Kremer I; Evers SMAA; Hiligsmann M
    Pharmacoeconomics; 2021 Jul; 39(7):789-807. PubMed ID: 33956330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic cost of dementia: A systematic review.
    Cantarero-Prieto D; Leon PL; Blazquez-Fernandez C; Juan PS; Cobo CS
    Dementia (London); 2020 Nov; 19(8):2637-2657. PubMed ID: 30909718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of Illness of Multiple Sclerosis - A Systematic Review.
    Ernstsson O; Gyllensten H; Alexanderson K; Tinghög P; Friberg E; Norlund A
    PLoS One; 2016; 11(7):e0159129. PubMed ID: 27411042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How much is the cost of multiple sclerosis--systematic literature review.
    Kolasa K
    Przegl Epidemiol; 2013; 67(1):75-9, 157-60. PubMed ID: 23745380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
    Rotstein Z; Hazan R; Barak Y; Achiron A
    Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of illness of multiple sclerosis: Part I: Cost of illness. The Canadian Burden of Illness Study Group.
    Can J Neurol Sci; 1998 Feb; 25(1):23-30. PubMed ID: 9532277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.
    Brown LJ; Li J; Brunner M; Snoke M; La HA
    J Med Econ; 2021; 24(1):140-149. PubMed ID: 33461357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of multiple sclerosis in Slovakia - from 2015 to 2020.
    Babela R; Dugas J
    BMC Health Serv Res; 2022 Dec; 22(1):1467. PubMed ID: 36461018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost burden of multiple sclerosis in the United States: a systematic review of the literature.
    Adelman G; Rane SG; Villa KF
    J Med Econ; 2013; 16(5):639-47. PubMed ID: 23425293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimate of the cost of multiple sclerosis in Spain by literature review.
    Fernández O; Calleja-Hernández MA; Meca-Lallana J; Oreja-Guevara C; Polanco A; Pérez-Alcántara F
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):321-333. PubMed ID: 28726515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review.
    Iragorri N; de Oliveira C; Fitzgerald N; Essue B
    Appl Health Econ Health Policy; 2021 May; 19(3):325-341. PubMed ID: 33368032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Societal costs of multiple sclerosis in Ireland.
    Carney P; O'Boyle D; Larkin A; McGuigan C; O'Rourke K
    J Med Econ; 2018 May; 21(5):425-437. PubMed ID: 29320900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The indirect costs of multiple sclerosis: systematic review and meta-analysis.
    Stawowczyk E; Malinowski KP; Kawalec P; Moćko P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):759-86. PubMed ID: 26189826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humanistic and cost burden of systemic sclerosis: A review of the literature.
    Fischer A; Zimovetz E; Ling C; Esser D; Schoof N
    Autoimmun Rev; 2017 Nov; 16(11):1147-1154. PubMed ID: 28899803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.
    Rodríguez-Sánchez B; Daugbjerg S; Peña-Longobardo LM; Oliva-Moreno J; Aranda-Reneo I; Cicchetti A; López-Bastida J
    Eur J Health Econ; 2023 Mar; 24(2):247-277. PubMed ID: 35596098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims.
    Bruno D; Marc D; Ouarda P; Dominique S; Marc S; Laurène C; Khalil J; Jonathan E; Francis G
    Mult Scler Relat Disord; 2019 Nov; 36():101396. PubMed ID: 31525627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of multiple sclerosis - extrapolation of Czech data to Polish patients.
    Szmurło D; Fundament T; Ziobro M; Kruntorádová K; Doležal T; Głogowski C
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):451-8. PubMed ID: 24702130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of multiple sclerosis in the Czech Republic: the COMS study.
    Blahova Dusankova J; Kalincik T; Dolezal T; Kobelt G; Havrdova E
    Mult Scler; 2012 May; 18(5):662-8. PubMed ID: 21965424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.